Clinical trial Recruiting at 1 site Observational Ages 18 to 60

Evaluating a new treatment for primary aldosteronism using adrenal artery embolization

Official title: The First Affiliated Hospital of Xinjiang Medical University

Run by Xinjiang Medical University · NCT06513676 · Data updated 2026-11-12

This study is testing a new treatment called adrenal artery embolization to see if it can help people with primary aldosteronism who can’t take medication or have surgery.

Quick facts

Study typeObservational
Ages18 Years to 60 Years
SexAll
Enrollment500 (estimated)
SponsorXinjiang Medical University
Academic / other
Locations1 site (Ürümqi, Xinjiang)
StatusRecruiting
StartedApril 15, 2024
Main results expectedJune 1, 2026
Study endsAugust 1, 2028
Registry record updatedJuly 23, 2024
Trial IDNCT06513676 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-60 diagnosed with primary hyperaldosteronism who cannot tolerate medication or surgery.

Probably not a fit

Patients with severe hypersensitivity to contrast media or other forms of secondary hypertension may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the efficacy and safety of adrenal vein blood extraction and super selective adrenal artery embolization (SAAE) for patients with primary aldosteronism. It involves a prospective, multicenter approach to classify types of primary hyperaldosteronism and explore SAAE as a potential treatment alternative for those who cannot tolerate medication or surgery. The study will provide new evidence for the diagnosis and treatment of this condition, promoting the development of SAAE as a viable option.

Why it matters

Potential benefit: If successful, this study could offer a new treatment option for patients with primary aldosteronism who have limited responses to existing therapies.

How similar studies have gone: While the approach of adrenal artery embolization is relatively novel, similar studies have shown promise in treating conditions related to hyperaldosteronism.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18-60 years old;
* Primary hyperaldosteronism was diagnosed in strict accordance with the 2016 International Endocrine Society clinical guidelines;
* Refusal of medication due to adverse reactions, refusal of adrenal resection due to surgical risk, or persistent hyperaldosteronism and cortical insufficiency after adrenal resection;
* The patients and their families were introduced in detail to all the current treatment methods for primary aldosteronism, and the adrenal artery embolization was voluntarily accepted;

Exclusion Criteria:

* A history of severe hypersensitivity to contrast media;
* There are serious complications of liver disease, such as thrombocytopenia, esophageal variceal bleeding, etc;
* Renal insufficiency (serum creatinine \> 176mmol/L or estimated glomerular filtration rate \< min.1.73m2);
* Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogens, herbs containing glycyrrhizin), pregnancy hypertension and other secondary hypertension;
* Hereditary diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesemia (Gitelman syndrome);
* Cerebral apoplexy, myocardial infarction and stent implantation occurred in the past 3 months;
* Serious other basic, such as heart dysfunction (grade IV), acute infection, autoimmune diseases, various malignant tumors and so on;
* Participated in other clinical trials within the past 3 months;
* Individual pregnancy, nursing or planning pregnancy;

Where it's running

  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.